1. Home
  2. TAK vs TCOM Comparison

TAK vs TCOM Comparison

Compare TAK & TCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TAK
  • TCOM
  • Stock Information
  • Founded
  • TAK 1781
  • TCOM 1999
  • Country
  • TAK Japan
  • TCOM Singapore
  • Employees
  • TAK N/A
  • TCOM N/A
  • Industry
  • TAK Biotechnology: Pharmaceutical Preparations
  • TCOM Hotels/Resorts
  • Sector
  • TAK Health Care
  • TCOM Consumer Discretionary
  • Exchange
  • TAK Nasdaq
  • TCOM Nasdaq
  • Market Cap
  • TAK 45.8B
  • TCOM 40.2B
  • IPO Year
  • TAK N/A
  • TCOM 2003
  • Fundamental
  • Price
  • TAK $14.68
  • TCOM $62.02
  • Analyst Decision
  • TAK
  • TCOM Strong Buy
  • Analyst Count
  • TAK 0
  • TCOM 10
  • Target Price
  • TAK N/A
  • TCOM $77.88
  • AVG Volume (30 Days)
  • TAK 2.3M
  • TCOM 2.8M
  • Earning Date
  • TAK 07-30-2025
  • TCOM 08-25-2025
  • Dividend Yield
  • TAK 3.70%
  • TCOM 0.48%
  • EPS Growth
  • TAK N/A
  • TCOM 51.63
  • EPS
  • TAK 0.45
  • TCOM 3.38
  • Revenue
  • TAK $30,595,075,281.00
  • TCOM $7,609,591,404.00
  • Revenue This Year
  • TAK $1.01
  • TCOM $17.32
  • Revenue Next Year
  • TAK $1.04
  • TCOM $14.47
  • P/E Ratio
  • TAK $65.09
  • TCOM $18.34
  • Revenue Growth
  • TAK 7.45
  • TCOM 16.95
  • 52 Week Low
  • TAK $12.80
  • TCOM $38.23
  • 52 Week High
  • TAK $15.53
  • TCOM $77.18
  • Technical
  • Relative Strength Index (RSI)
  • TAK 41.31
  • TCOM 57.27
  • Support Level
  • TAK $14.93
  • TCOM $60.20
  • Resistance Level
  • TAK $15.14
  • TCOM $62.22
  • Average True Range (ATR)
  • TAK 0.15
  • TCOM 1.07
  • MACD
  • TAK -0.06
  • TCOM 0.47
  • Stochastic Oscillator
  • TAK 11.86
  • TCOM 89.71

About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

About TCOM Trip.com Group Limited

Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.

Share on Social Networks: